Adagio Therapeutics, Inc. held its Annual Meeting of Stockholders on June 22, 2022, elected Tamsin Berry, Marc Elia and Clive Meanwell as Class I directors, each to serve for a three-year term expiring at the 2025 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified.